CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration

The BMJ

Volumn 350, Issue , 2015, Pages

  Shamseer, Larissa ^a   Sampson, Margaret ^b   Bukutu, Cecilia ^c   Schmid, Christopher H ^d   Nikles, Jane ^e   Tate, Robyn ^f   Johnston, Bradley C ^g   Zucker, Deborah ^h   Shadish, William R ⁱ   Kravitz, Richard ^j   Guyatt, Gordon ^k   Altman, Douglas G ^l   Moher, David ^a   Vohra, Sunita ^m  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c Alberta Centre for Child Family and Community Research   (Canada)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k MCMASTER UNIVERSITY   (Canada)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHECKLIST; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; REVIEW; DECISION MAKING; EVIDENCE BASED MEDICINE; NOMENCLATURE; PUBLISHING; QUALITY CONTROL;

CHECKLIST; CROSS-OVER STUDIES; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; PUBLISHING; QUALITY CONTROL; TERMINOLOGY AS TOPIC;

EID: 84939459399     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2015.05.018     Document Type: Article

References (122)

1. Gitterman DP, Hay WW Jr. That sinking feeling, again? the state of national institutes of health pediatric research funding, fiscal year 1992-2010. Pediatr Res 2008;64:462.
2. Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ 2014;349:g6802.
3. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med 2006;4:104-8.
4. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine. Soc Psychiatry Psychiatr Epidemiol 2005;40:27-35.
5. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 2009;62:499-505.
6. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005;3:223-8.
7. Van den Akker M, Buntinx F, Metsemakers JFM, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998;51:367-75.
8. Zucker DR, Schmid CH, McIntosh MW, D’Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol 1997;50:401-10.
9. Guyatt G, Jaeschke R, McGinn T. Part 2B1: therapy and validity. N-of-1 randomized controlled trials. In: Guyatt G, Rennie D, Meade MO, Cook DJ, eds. Users’ guides to the medical literature . American Medical Association, 2002:275-90.
10. OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 2 . Oxford Centre for Evidence-Based Medicine, 2011. www.cebm.net/index.aspx?o=5653.
11. Kravitz RL, Duan N, eds, and the DEcIDE Methods Center N-of-1 Guidance Panel. Design and implementation of N-of-1 trials: a user’s guide . AHRQ Publication No 13(14)-EHC122-EF. Agency for Healthcare Research and Quality, 2014. www.effectivehealthcare.ahrq.gov/N-1-Trials.cfm.
12. Punja S, Bukutu C, Shamseer L, Sampson M, Hartling L, Urichuk L, et al. Systematic review of the methods, statistical analysis and meta-analysis of N-of-1 trials [dissertation]. University of Alberta, 2014.
13. Hersen. Single case experimental designs: strategies for studying behaviour change . Peragmon Press, 1976.
14. Kazdin A. Single case research designs: methods for clinical and applied settings . Oxford University Press, 1982.
15. Barlow DH, Hersen M. Single case experimental designs: strategies for studying behavior change . Pergamon Press, 1984.
16. Tate RL, McDonald S, Perdices M, Togher L, Schultz R, Savage S. Rating the methodological quality of single-subject designs and n-of-1 trials: Introducing the single-case experimental design (SCED) scale. Neuropsychol Rehabil 2008;18:385-401.
17. Tate RL, Perdices M, Rosenkoetter U, Wakim D, Godbee K, Togher L, et al. Revision of a method quality rating scale for single-case experimental designs and n-of-1 trials: the 15-item risk of bias in N-of-1 trials (RoBiNT) scale. Neuropsychol Rehabil 2013;23:619-38.
18. Guyatt G, Jaeschke R, McGinn T. N-of-1 randomized controlled trials. In: Guyatt G, Rennie D, Meade MO, Cook DJ, eds. Users’ guides to the medical literature: a manual for evidence-based clinical practice . 2nd ed. McGraw-Hill, 2008.
19. Gabler NB, Duan N, Vohra S, Kravitz RL. N-of-1 trials in the medical literature: a systematic review. Med Care 2011;49:761-8.
20. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014;383:267-76.
21. Tate R, Togher L, Perdices M, McDonald S, Rosenkoetter U, on behalf of the SCRIBE Steering Committee. Developing reporting guidelines for single-case experimental designs: the SCRIBE project. Brain Impairment 2012;13:135.
22. Schulz K, Altman D, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010;8:18.
23. Turner L, Moher D, Shamseer L, Weeks L, Peters J, Plint A, et al. The influence of CONSORT on the quality of RCTs: an updated review. 9th Annual Cochrane Canada Symposium, February 16-17, 2011.
24. Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ 2015;350:h1738.
25. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7:e1000217.
26. Enhancing reproducibility. Nature Methods 2013;10:367.
27. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1-37.
28. Price JD, Grimley EJ. An N-of-1 randomized controlled trial (‘N-of-1 trial’) of donepezil in the treatment of non-progressive amnestic syndrome. Age Ageing 2002;31:307-9.
29. Wegman AC, van der Windt DA, Bongers M, Twisk JW, Stalman WA, de Vries TP. Efficacy of temazepam in frequent users: a series of N-of-1 trials. Fam Pract 2005;22:152-9.
30. Träder J. Mutterkraut als prophylaktische phytotherapie bei migräne: N-of-1-studie zum individuellen wirksamkeitsnachweis [feverfew as preventive therapy for migraine: N-of-1-trial for verification of individual efficacy]. ZFA 2007;83:238-41.
31. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 2008;371:281-3.
32. Nonoyama ML, Brooks D, Guyatt GH, Goldstein RS. Effect of oxygen on health quality of life in COPD patients with transient exertional hypoxemia. Am J Respir Crit Care Med 2007;176:343-9.
33. Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. Are brand-name and generic warfarin interchangeable? multiple n-of-1 randomized, crossover trials. Ann Pharmacother 2005;39:1188-93.
34. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 2009;62:499-505.
35. Kamien M. The use of an N-of-1 randomised clinical trial in resolving therapeutic doubt. the case of a patient with an ‘attention disorder’. Aust Fam Physician 1998;27(suppl 2):S103-5.
36. Sung L, Tomlinson GA, Greenberg ML, Koren G, Judd P, Ota S, et al. Serial controlled N-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur J Cancer 2007;43:1269-75.
37. Louly PG, Medeiros-Souza P, Santos-Neto L. N-of-1 double-blind, randomized controlled trial of tramadol to treat chronic cough. Clin Ther 2009;31:1007-13.
38. Wegman AC, van der Windt DA, de HM, Deville WL, Fo CT, de Vries TP. Switching from NSAIDs to paracetamol: a series of n of 1 trials for individual patients with osteoarthritis. Ann Rheum Dis 2003;62:1156-61.
39. Smith BJ, Appleton SL, Veale AJ, McElroy HJ, Veljkovic D, Saccoia L. Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol. Chron Respir Dis 2004;1:63-9.
40. Chin R, Chin RY, Lee BY. Principles and practice of clinical trial medicine . Academic Press, 2008.
41. Johannessen T, Petersen H, Kristensen P, Fosstvedt D, Kleveland PM, Dybdahl J, et al. Cimetidine on-demand in dyspepsia. experience with randomized controlled single-subject trials. Scand J Gastroenterol 1992;27:189-95.
42. Fedele DJ, Jones JA, Volicer L, Herz LR, Oppenheim FG. Effects of medication on parotid salivary flow rates in an individual with dementia of the alzheimer type. Spec Care Dentist 1993;13:215-8.
43. Coxeter PD, Schluter PJ, Eastwood HL, Nikles CJ, Glasziou PP. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement Ther Med 2003;11:215-22.
44. Nathan PC, Tomlinson G, Dupuis LL, Greenberg ML, Ota S, Bartels U, et al. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a bayesian randomized serial N-of-1 trials design. Support Care Cancer 2006;14:268-76.
45. Irwig L, Glasziou P, March L. Ethics of n-of-1 trials. Lancet 1995;345:469.
46. Mahon JL, Feagan BG, Laupacis A. Ethics of n-of-1 trials. Lancet 1995;345:989.
47. Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol 2010;63:1312-23
48. Punja S, Eslick I, Duan N, Vohra S, the DEcIDE Methods Center N-of-1 Guidance Panel. Chapter 2: An ethical framework for N-of-1 trials: clinical care, quality improvement, or human subjects research? In: Kravitz RL, Duan N, and the DEcIDE Methods Center N-of-1 Guidance Panel, eds. Design and implementation of N-of-1 trials: a user’s guide . AHRQ Publication No 13(14)-EHC122-EF. Agency for Healthcare Research and Quality, 2014:13-22.
49. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy--randomized trials in individual patients. N Engl J Med. 1986;314:889-92.
50. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687.
51. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: An elaborated CONSORT statement. Ann Intern Med 2006;144:364-7.
52. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol 2006;59:1134-49.
53. MacPherson H, Altman DG, Hammerschlag R, Li Y, Wu T, White A, et al. Revised STandards for reporting interventions in clinical trials of acupuncture (STRICTA): Extending the CONSORT statement. Acupunct Med 2010;28:83.
54. Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, for the CONSORT group. Methods and processes of the CONSORT group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med 2008;148:W60-7.
55. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008;148:295.
56. McLeod RS, Taylor DW, Cohen Z, Cullen JB. Single-patient randomised clinical trial. use in determining optimum treatment for patient with inflammation of Kock continent ileostomy reservoir. Lancet 1986;1:726-8.
57. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic review of the empirical evidence of study publication bias and outcome reporting bias—an updated review. PloS One 2013;8:e66844.
58. Guyatt G, Montori V, Devereaux PJ, Schünemann H, Bhandari M. Patients at the center: in our practice, and in our use of language. ACP J Club 2004;140:A11-2.
59. Guyatt GH, Jaeschke R, Roberts R. N-of-1 randomized clinical trials in pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology . Wiley, 2005:665-80.
60. Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, et al. Patient-important outcomes in registered diabetes trials. JAMA 2008;299:2543.
61. Paterson C. Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey. BMJ 1996;312:1016.
62. Paterson C, Allen JA, Browning M, Barlow G, Ewings P. A pilot study of therapeutic massage for people with parkinson’s disease: the added value of user involvement. Complement Ther Clin Pract 2005;11:161-71.
63. Dziegielewski SF. Eye movement desensitization and reprocessing (EMDR) as a time-limited treatment intervention for body image disturbance and self-esteem: a single subject case study design. J Psychother Independent Pract 2000;1:1-16.
64. Johnston BC, Shamseer L, da Costa BR, Tsuyuki RT, Vohra S. Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. Pediatrics 2010;126:e222.
65. Sinha IP, Altman DG, Beresford MW, Boers M, Clarke M, Craig J, et al. Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. Pediatrics 2012;129(suppl 3):S146-52.
66. Miyar J, Adams CE. Content and quality of 10,000 controlled trials in schizophrenia over 60 years. Schizophr Bull 2013;39:226-9.
67. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry 2000;176:249-52.
68. Kirkham JJ, Altman DG, Williamson PR. Bias due to changes in specified outcomes during the systematic review process. PLoS One 2010;5:e9810.
69. Zwaigenbaum L, Dick P, Handley-Derry M, Malone M, Jacobson SE. “N of 1” trials of methylphenidate in two children with Williams syndrome and attention deficit hyperactivity disorder. J Dev Phys Disabil 2006;18:45-58.
70. Nikles J, Mitchell GK, Schluter P, Good P, Hardy J, Rowett D, et al. Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. J Clin Epidemiol 2011;64:471-80.
71. Cepeda MS, Acevedo JC, Alvarez H, Miranda N, Cortes C, Carr DB. An N-of-1 trial as an aid to decision-making prior to implanting a permanent spinal cord stimulator. Pain Med 2008;9:235-9.
72. Montori VM, Devereaux P, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203.
73. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. Stopping randomized trials early for benefit and estimation of treatment effects. JAMA 2010;303:1180-7.
74. Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM. Problems of stopping trials early. BMJ 2012;344:e3863.
75. Nikles CJ, Yelland M, Glasziou PP, Del MC. Do individualized medication effectiveness tests (n-of-1 trials) change clinical decisions about which drugs to use for osteoarthritis and chronic pain? Am J Ther 2005;12:92-7.
76. Morrow KL, Fridriksson J. Comparing fixed- and randomized-interval spaced retrieval in anomia treatment. J Commun Disord 2006;39:2-11.
77. Schmid CH, Duan N, the DEcIDE Methods Center N-of-1 Guidance Panel. Chapter 4: Statistical design and analytic considerations for N-of-1 trials. In: Kravitz RL, Duan N, DEcIDE Methods Center N-of-1 Guidance Panel, eds. Design and implementation of N-of-1 trials: a user’s guide . AHRQ Publication No 13(14)-EHC122-EF ed. Agency for Healthcare Research and Quality, 2014:33-53.
78. Woodfield R, Goodyear-Smith F, Arroll B. N-of-1 trials of quinine efficacy in skeletal muscle cramps of the leg. Br J Gen Pract 2005;55:181-5.
79. Price JD, Grimley EJ. N-of-1 randomized controlled trials (‘N-of-1 trials’): singularly useful in geriatric medicine. Age Ageing 2002;31:227-32.
80. Arroll B, Miller P. Single case randomised trial of tryptophan vs placebo. NZ Fam Physician 1989;16:14-5.
81. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Ann Intern Med 1997;126:36-47.
82. Gage NA, Lewis TJ. Analysis of effect for single-case design research. J Appl Sport Psychol 2013;25:46-60.
83. Horner RH, Swaminathan H, Sugai G, Smolkowski K. Considerations for the systematic analysis and use of single-case research. Educ Treat Child 2012;35:269-90.
84. Parker RI, Vannest KJ, Davis JL. Effect size in single-case research: a review of nine nonoverlap techniques. Behav Modif 2011;35:303-22.
85. Heyvaert M, Wendt O, Van den Noortgate W, Onghena P. Randomization and data-analysis items in quality standards for single-case experimental studies. J Special Educ 2014; doi:0022466914525239.
86. Shadish WR. Statistical analyses of single-case designs the shape of things to come. Curr Direct Psychol Sci 2014;23:139-46.
87. Altman DG. Confidence intervals in practice. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence . 2nd ed. BMJ Books, 2000:6-14.
88. Altman DG. Clinical trial and meta-analyses. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence . 2nd ed. BMJ Books, 2000:120-38.
89. Bailar JC 3rd, Mosteller F. Guidelines for statistical reporting in articles for medical journals. amplifications and explanations. Ann Intern Med 1988;108:266-73.
90. Zucker DR, Ruthazer R, Schmid CH, Feuer JM, Fischer PA, Kieval RI, et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol 2006;33:2069-77.
91. Maggin DM, O’Keeffe BV, Johnson AH. A quantitative synthesis of methodology in the meta-analysis of single-subject research for students with disabilities: 1985–2009. Exceptionality 2011;19:109-35.
92. Gage NA, Lewis TJ. Hierarchical linear modeling meta-analysis of single-subject design research. J Special Educ 2012; doi:0022466912443894.
93. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:c221.
94. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.
95. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-e34.
96. Haas DC, Sheehe PR. Dextroamphetamine pilot crossover trials and n of 1 trials in patients with chronic tension-type and migraine headache. Headache 2004;44:1029-37.
97. Senn S. Cross-over trials in clinical research . 2nd ed. Wiley, 2002.
98. Maggin DM, Swaminathan H, Rogers HJ, O’Keeffe BV, Sugai G, Horner RH. A generalized least squares regression approach for computing effect sizes in single-case research: application examples. J School Psychol 2011;49:301-21.
99. Rochon J. A statistical model for the “N-of-1” study. J Clin Epidemiol 1990;43:499-508.
100. Parker RI, Hagan-Burke S, Vannest K. Percentage of all non-overlapping data (PAND) an alternative to PND. J Special Educ 2007;40:194-204.
101. Johnston MV, Smith RO. Single subject designs: current methodologies and future directions. OTJR 2010;30:4.
102. Gordon K, Bawden H, Camfield P, Mann S, Orlik P. Valproic acid treatment of learning disorder and severely epileptiform EEG without clinical seizures. J Child Neurol 1996;11:41-3.
103. Dales RE, Lunau MA, Tierney MG, Schweitzer I. Chronic cough responsive to ibuprofen. Pharmacotherapy 1992;12:331-3.
104. Estrada CA, Young MJ. Patient preferences for novel therapy: an N-of-1 trial of garlic in the treatment for hypertension. J Gen Intern Med 1993;8:619-21.
105. Lehman R, Loder E. Missing clinical trial data. BMJ 2012;344:d8158.
106. AllTrials. All trials registered: all results reported. www.alltrials.net.
107. Avins AL, Bent S, Neuhaus JM. Use of an embedded N-of-1 trial to improve adherence and increase information from a clinical study. Contemp Clin Trials 2005;26:397-401.
108. Reed JF III. AB/BA crossover trials-binary outcome. J Mod App Stat Meth 2005;5:19.
109. Johannessen T, Kristensen P, Petersen H, Fosstvedt D, Loge I, Kleveland PM, et al. The symptomatic effect of 1-day treatment periods with cimetidine in dyspepsia. combined results from randomized, controlled, single-subject trials. Scand J Gastroenterol 1991;26:974-80.
110. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM. Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford) 2007;46:135-40.
111. Van RR, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995;9:49-53.
112. Hoffmeyer CA. A multiple single-case study experimental design exploring the effect of therapeutic touch on women with migraine headaches [dissertation]. University of Colorado Health Sciences Center, 2000.
113. Nikles CJ, Mitchell GK, Del Mar CB, Clavarino A, McNairn N. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder. Pediatrics 2006;117:2040-6.
114. Tison F, Nègre-Pagès L, Meissner WG, Dupouy S, Li Q, Thiolat M, et al. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in parkinson’s disease patients. Parkinsonism Relat Disord 2013;19:416-21.
115. De Angelis C, Drazen JM, Frizelle PFA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the international committee of medical journal editors. N Engl J Med 2004;351:1250-1.
116. Food and Drug Administration Amendment Act of 2007, Title VIII, Section 801. 2007). See: www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/foodanddrugadministrationamendmentsactof2007/ default.htm.
117. Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK, et al. Leptin replacement improves cognitive development. PLoS One. 2008;3:e3098.
118. Chan AW, Hróbjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
119. Moher D. Reporting research results: a moral obligation for all researchers. Can J Anaesth 2007;54:331-5.
120. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Obstet Gynecol 2009;114:1341-5.
121. Carry over. Glossary of Cochrane terms 2013. www.cochrane.org/glossary/5#term137.
122. Campbell MJ, Machin D, Walters SJ. Medical statistics: a textbook for the health sciences . John Wiley, 2010.